Search
Bioymifi
go.drugbank.com/drugs/DB17493ExperimentalUpon binding to the death receptor 5 (DR5) on cancer cells, bioymifi triggers apoptosis, possibly through a caspase-dependent pathway. Bioymifi is currently being investigated as an anti-tumor agent. … Bioymifi is a small molecule that acts as a tumor necrosis factor-related apoptosis-induced ligand (TRAIL) mimetic.
Mimosine
go.drugbank.com/drugs/DB01055ExperimentalMimosine is an antineoplastic alanine-substituted pyridine derivative isolated from _Leucena glauca_.
Potassium guaiacolsulfonate
go.drugbank.com/drugs/DB13735ApprovedWithdrawnGuaiacolsulfonate is an aromatic sulfonic acid. Potassium guaiacolsulfonate salt is an expectorant that thins the mucus in the lungs and reduces chest congestion.
Nedocromil
go.drugbank.com/drugs/DB00716ApprovedA pyranoquinolone derivative that inhibits activation of inflammatory cells which are associated with asthma, including eosinophils, neutrophils, macrophages, mast cells, monocytes, and platelets.
ZD4407
go.drugbank.com/drugs/DB06539ExperimentalIt entered Phase 1 clinical trials for chronic obstructive pulmonary disease (COPD) in the United Kingdom but was discontinued during this phase in March 2003 … The drug ZD4407, an antiasthmatic developed by AstraZeneca, functions as a 5-lipoxygenase inhibitor.
Rosmarinic acid
go.drugbank.com/drugs/DB16865InvestigationalCategories: Compounds used in a research, industrial, or household settingClothiapine
go.drugbank.com/drugs/DB13256ApprovedClothiapine has been approved in European countries and is an atypical antipsychotic, shown to be useful in some treatment-resistant patients.
Tolperisone
go.drugbank.com/drugs/DB06264InvestigationalIt possesses a high affinity for nervous system tissue, reaching highest concentrations in brain stem, spinal cord and peripheral nerves. … Tolperisone is an oral, centrally acting muscle relaxant. Its precise mechanism is not completely understood, though it blocks sodium and calcium channels.
Ibudilast
go.drugbank.com/drugs/DB05266InvestigationalIbudilast is currently in development in the U.S. (codes: AV-411 or MN-166), but is approved for use as an antiinflammatory in Japan. … shrinkage in patients with relapsing-remitting (RR) and/or secondary progressive (SP) multiple sclerosis (MS).